Stay updated with breaking news from Preliminary Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical TrialMILAN, Italy and NEW YORK, Feb. 08, 2024 -- Genenta Science , a clinical-stage immuno-oncology company...
– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN...
– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 -- Alterity...
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of...
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF